Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial. (bmj.com)

Authors: You R … Chen MY Journal: BMJ Published: 2026-02-10 DOI: https://doi.org/10.1136/bmj-2025-085863